tiprankstipranks
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
PremiumPress ReleasesAIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
10d ago
AIM ImmunoTech announces interim report data from Ampligen study
PremiumThe Fly
AIM ImmunoTech announces interim report data from Ampligen study
10d ago
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
PremiumPress Releases
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
18d ago
AIM ImmunoTech announces publication of findings from Ampligen study
PremiumThe FlyAIM ImmunoTech announces publication of findings from Ampligen study
26d ago
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
PremiumPress Releases
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
26d ago
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
PremiumPress Releases
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
29d ago
AIM ImmunoTech launches CEO Corner platform
PremiumThe FlyAIM ImmunoTech launches CEO Corner platform
1M ago
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
PremiumPress Releases
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
2M ago
AIM ImmunoTech outlines recent progress across development pipeline
PremiumThe Fly
AIM ImmunoTech outlines recent progress across development pipeline
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100